Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: a randomized crossover study

Table 3 Correlations between FMD and lipid and glucose parameters at baseline and postprandially, and changes in these parameters in response to the cookie test in the bezafibrate group

Dependent variable, FMD	Baseline		4 h		Change
	r	p	r	p	r	p
TG	-0.33	0.35	-0.21	-0.60	-0.41	0.24
RLP-C	-0.39	0.27	-0.15	0.68	-0.26	0.47
ApoB-48	-0.39	0.27	-0.29	0.42	-0.37	0.29
	Baseline		2 h		Change
	r	p	r	p	r	p
Glucose	-0.47	0.17	-0.51	0.13	0.004	0.99
Insulin	-0.33	0.36	-0.41	0.24	0.14	0.7
HOMA-R	-0.38	0.27	-0.47	0.17	0.16	0.66

FMD, flow-mediated dilation; TG, triglyceride; RLP-C, remnant lipoprotein cholesterol; ApoB-48, apolipoprotein B-48; HOMA-R, Homeostasis model assessment ratio.

ISSN: 1475-2840